Correction: Acetate from Cancer Fibroblasts Fuels Pancreatic Cancer via Polyamine Metabolism
This is an author correction regarding a previously published article. The original article, titled 'Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis,' has been amended. The correction pertains to the specific mechanisms and pathways involved in how acetate, produced by cancer-associated fibroblasts, influences pancreatic cancer progression. The core finding remains that this acetate plays a role in promoting cancer development. This promotion is achieved by altering the body's polyamine metabolism. The specific molecular axis identified in this process is ACSS2–SP1–SAT1. The correction clarifies the precise interactions within this pathway and its downstream effects on cancer cells. It emphasizes the critical link between fibroblast metabolism and tumor growth. The study aims to provide a deeper understanding of the tumor microenvironment's metabolic contributions to pancreatic cancer. This knowledge could potentially lead to new therapeutic strategies targeting these metabolic vulnerabilities.
This correction highlights the iterative nature of scientific discovery, particularly in complex fields like cancer biology. The initial publication identified a specific metabolic pathway involving acetate, fibroblasts, and pancreatic cancer progression. The correction suggests a refinement of the understanding of the ACSS2–SP1–SAT1 axis and its precise role in polyamine metabolism. Such adjustments are crucial for building robust scientific consensus and ensuring the accuracy of research findings that inform potential therapeutic interventions. Understanding these intricate metabolic dependencies within the tumor microenvironment is increasingly vital as we move into an era where personalized medicine and targeted therapies are paramount. Future research will likely focus on validating these metabolic targets and assessing their efficacy and safety in clinical settings, considering the potential for off-target effects and the heterogeneity of cancer.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.
